secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001919246-26-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos Q4 ZELSUVMI sales $9.1M, up 28% QoQ; adds XEPI and XEGLYZE
------------------------------------------------------------------

- ZELSUVMI net product revenue $9.1M in Q4 2025 vs $7.1M in Q3; full-year 2025 total revenue $16.8M.
- 8,948 units dispensed, 2,712 unique prescribers; Q4 units up 129% QoQ to 6,232.
- Acquired XEPI (impetigo) Nov 2025 and XEGLYZE (head lice) Jan 2026; sales force expanded to 64.
- Closed $18M convertible notes Nov 2025 and $50M term loan ($30M drawn) Jan 2026; cash $18M at year-end.
- Operating loss improved to $12M in Q4 from $15.4M in Q3; adjusted EBITDA loss improved 22% QoQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000014/0001919246-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000014/pths-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001919246-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer